Aquestive Therapeutics 近日公布了其明星产品 Anaphylm™（二丁基肾上腺素）舌下膜剂的人因工程与药代动力学研究的积极顶线结果。这一成果标志着该候选药物在过敏性反应紧急治疗领域迈出了关键一步。研究数据表明，在模拟真实使用场景的人因工程测试中，受试者能够正确、迅速地完成给药操作；同时，药代动力学分析显示，药物吸收迅速，血药浓度达峰时间理想，展现出良好的生物利用度。
Aquestive Therapeutics 近日公布了其明星产品 Anaphylm™（二丁基肾上腺素）舌下膜剂的人因工程与药代动力学研究的积极顶线结果。这一成果标志着该候选药物在过敏性反应紧急治疗领域迈出了关键一步。研究数据表明，在模拟真实使用场景的人因工程测试中，受试者能够正确、迅速地完成给药操作；同时，药代动力学分析显示，药物吸收迅速，血药浓度达峰时间理想，展现出良好的生物利用度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.